LOGIN  |  REGISTER
Astria Therapeutics
Viking Therapeutics

Acadia Healthcare to Participate in BofA Securities Health Care Conference

May 08, 2025 | Last Trade: US$21.09 0.68 -3.12

FRANKLIN, Tenn. / May 08, 2025 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference, May 13-15, 2025, in Las Vegas, Nevada.

In connection with the conference, there will be an online webcast of the Company’s presentation available on the Company’s website starting at 1:20 p.m. Central Time / 11:20 a.m. Pacific Time on Wednesday, May 14th, 2025.

The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentation will also be available on the Company’s website for 30 days.

About Acadia

Acadia is a leading provider of behavioral healthcare services across the United States. As of December 31, 2024, Acadia operated a network of 262 behavioral healthcare facilities with approximately 11,850 beds in 39 states and Puerto Rico. With approximately 25,500 employees serving more than 80,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page